instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
Can you tell me the median Progression-Free Survival rate in patients who were treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What’s the median PFS rate for patients receiving Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What’s the median PFS rate for patients receiving Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Could you provide the median Progression-Free Survival rate for patients treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What is the median rate of Progression-Free Survival in patients who have been treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Can you inform me about the median PFS rate in patients that were treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What is the median PFS rate for patients that have undergone Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What is the median PFS rate for patients that have undergone Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Could you tell me the median Progression-Free Survival rate for patients who received Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What’s the median rate of PFS in patients treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What’s the median rate of PFS in patients treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Can you share the median Progression-Free Survival rate in patients who have received Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Can you tell me the median PFS for Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Can you tell me the median PFS for Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What’s the median PFS associated with Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What’s the median PFS associated with Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Could you provide the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Could you provide the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
I’d like to know the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd). | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: I’d like to know the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd).
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Do you have information on the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Do you have information on the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What is the median progression-free survival (PFS) for Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What is the median progression-free survival (PFS) for Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Can you inform me about the median PFS for Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Can you inform me about the median PFS for Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
I’m interested in the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd). | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: I’m interested in the median PFS of Isatuximab+Pomalidomide+Dexamethasone (IPd).
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Could you tell me the median PFS for Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Could you tell me the median PFS for Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What is the median PFS rate for Isatuximab+Pomalidomide+Dexamethasone (IPd)? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What is the median PFS rate for Isatuximab+Pomalidomide+Dexamethasone (IPd)?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What is the median PFS rate in patients who have undergone Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What is the median PFS rate in patients who have undergone Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What’s the median PFS rate for patients receiving Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What’s the median PFS rate for patients receiving Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Could you provide the median Progression-Free Survival rate for patients treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What is the median rate of Progression-Free Survival in patients who have been treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Can you inform me about the median PFS rate in patients that were treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What is the median PFS rate for patients that have undergone Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What is the median PFS rate for patients that have undergone Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Could you tell me the median Progression-Free Survival rate for patients who received Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
What’s the median rate of PFS in patients treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: What’s the median rate of PFS in patients treated with Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Can you share the median Progression-Free Survival rate in patients who have received Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen? | Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Isatuximab+Pomalidomide+Dexamethasone (IPd) regimen?
### Response: Patients treated with the Isatuximab+Pomalidomide+Dexamethasone (IPd) have a median Progression-Free Survival (PFS) rate of 11.1 months, with a 95% CI of (7.5, 14.8). |
Can you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Can you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What’s the median PFS associated with Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What’s the median PFS associated with Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Could you provide the median PFS of Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Could you provide the median PFS of Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
I’d like to know the median PFS of Pomalidomide+Dexamethasone (Pd). | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: I’d like to know the median PFS of Pomalidomide+Dexamethasone (Pd).
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Do you have information on the median PFS of Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Do you have information on the median PFS of Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Can you inform me about the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Can you inform me about the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
I’m interested in the median PFS of Pomalidomide+Dexamethasone (Pd). | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: I’m interested in the median PFS of Pomalidomide+Dexamethasone (Pd).
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Could you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Could you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What is the median PFS rate for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What is the median PFS rate for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 6.5 months, with a 95% CI of (4.7, 7.9). |
Can you tell me the median PFS for Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Can you tell me the median PFS for Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What’s the median PFS associated with Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What’s the median PFS associated with Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Could you provide the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Could you provide the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
I’d like to know the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd). | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: I’d like to know the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd).
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Do you have information on the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Do you have information on the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What is the median progression-free survival (PFS) for Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What is the median progression-free survival (PFS) for Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Can you inform me about the median PFS for Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Can you inform me about the median PFS for Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
I’m interested in the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd). | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: I’m interested in the median PFS of Selinexor+Bortezomib+Dexamethasone (SVd).
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Could you tell me the median PFS for Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Could you tell me the median PFS for Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What is the median PFS rate for Selinexor+Bortezomib+Dexamethasone (SVd)? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What is the median PFS rate for Selinexor+Bortezomib+Dexamethasone (SVd)?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What is the median PFS rate in patients who have undergone Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What is the median PFS rate in patients who have undergone Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What’s the median PFS rate for patients receiving Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What’s the median PFS rate for patients receiving Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Could you provide the median Progression-Free Survival rate for patients treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What is the median rate of Progression-Free Survival in patients who have been treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Can you inform me about the median PFS rate in patients that were treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What is the median PFS rate for patients that have undergone Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What is the median PFS rate for patients that have undergone Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Could you tell me the median Progression-Free Survival rate for patients who received Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
What’s the median rate of PFS in patients treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: What’s the median rate of PFS in patients treated with Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Can you share the median Progression-Free Survival rate in patients who have received Selinexor+Bortezomib+Dexamethasone (SVd) regimen? | Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Selinexor+Bortezomib+Dexamethasone (SVd) regimen?
### Response: Patients treated with the Selinexor+Bortezomib+Dexamethasone (SVd) have a median Progression-Free Survival (PFS) rate of 13.93 months, with a 95% CI of (11.7, NE). |
Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd). | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd). | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What is the median PFS rate for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What is the median PFS rate for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 9.46 months, with a 95% CI of (8.1, 10.8). |
Can you tell me the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Can you tell me the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What’s the median PFS associated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What’s the median PFS associated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Could you provide the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Could you provide the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
I’d like to know the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd). | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: I’d like to know the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd).
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Do you have information on the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Do you have information on the median PFS of Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
What is the median progression-free survival (PFS) for Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Can you inform me about the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)? | Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). | ### Instruction: Can you inform me about the median PFS for Daratumumab+Carfilzomib+Dexamethasone (DKd)?
### Response: Patients treated with the Daratumumab+Carfilzomib+Dexamethasone (DKd) have a median Progression-Free Survival (PFS) rate of 28.4 months, with a 95% CI of (22.7, 36.2). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.